ramelteon and doxepin
ramelteon has been researched along with doxepin in 4 studies
Compound Research Comparison
| Studies (ramelteon) | Trials (ramelteon) | Recent Studies (post-2010) (ramelteon) | Studies (doxepin) | Trials (doxepin) | Recent Studies (post-2010) (doxepin) |
|---|---|---|---|---|---|
| 317 | 59 | 204 | 885 | 207 | 129 |
Protein Interaction Comparison
| Protein | Taxonomy | ramelteon (IC50) | doxepin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.046 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.029 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.258 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.042 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.2 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.026 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.6675 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.077 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.2 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0355 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.5145 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.8595 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.069 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.688 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.029 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.867 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.118 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.038 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.046 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.8595 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.2 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.2 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.2 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.2 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.042 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.2 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.2 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.2 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0006 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.393 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.2 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.089 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 1.6 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.32 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.2 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.631 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.2 |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chung, KF; Ng, TH; Yeung, WF; Yung, KP | 1 |
| Edmonds, C; Swanoski, M | 1 |
Reviews
3 review(s) available for ramelteon and doxepin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Doxepin for insomnia: a systematic review of randomized placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Doxepin; Drug Therapy, Combination; Female; Humans; Indenes; Male; Middle Aged; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Treatment Outcome; United States; United States Food and Drug Administration; Young Adult | 2015 |
A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Topics: Aged; Aged, 80 and over; Azepines; Benzofurans; Cyclopropanes; Doxepin; Humans; Hypnotics and Sedatives; Indenes; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; Triazoles | 2017 |
Other Studies
1 other study(ies) available for ramelteon and doxepin
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |